

Best of ASCO 2014 in Japan プログラム

as of 2014/06/12

※本セミナーでとりあげる演題は、2014年5月30日～6月3日に開催される米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに * 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

7月5日（土曜日）

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00-10:05	Welcome & Introduction				
	石岡 千加史 東北大学				
10:05-10:35	血液がん - Leukemia 南 陽介 神戸大学	飯田 真介 名古屋市立大学	7005	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (t/r ALL).	Max S. Topp
			LBA7008	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.	John C. Byrd
			7026	Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial	Srdan Verstovsek
10:35-10:45	Discussion: Q&A				
10:45-11:25	血液がん - Lymphoma and Myeloma 鈴木 達也 国立がん研究センター中央病院	石塚 賢治 福岡大学	8501	Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.	Michael Pfreundschuh
			8510	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.	Paul G. Richardson
			8511	E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).	A. Keith Stewart
			8520	Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study.	Grzegorz S. Nowakowski
11:25-11:40	Discussion: Q&A				
11:40-12:10	Developmental Therapeutics 藤原 豊 国立がん研究センター中央病院	村上 晴泰 静岡県立静岡がんセンター	*2501	Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.	Rastislav Bahleda
			*2527	A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.	Scott Andrew Laurie, MD, FRCP
			*3007	A phase 1 study of PF 05082566 (anti-4-1BB) in patients with advanced cancer.	Neil Howard Segal
12:10-12:20	Discussion: Q&A				
12:20-12:35	Break				
12:35-13:35	[ランチョンセミナー] Prof. Tony Mok The Chinese University of Hong Kong in Prince of Wales Hospital	里内 美弥子 兵庫県立がんセンター	What happen to the world of EGFR mutation after ASCO 2014? *同時通訳 日本イーライリリ-株式会社		
13:35-13:50	Break				
13:50-14:20	消化器がん - Colorectal Cancer 山崎 健太郎 静岡県立静岡がんセンター	水沼 信之 がん研有明病院	LBA3	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).	Alan P. Venook
			3500	Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.	Claus Rodel
			3503	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).	Dirk Arnold
14:20-14:30	Discussion: Q&A				
14:30-15:00	消化器がん - Noncolorectal Cancer 廣中 秀一 千葉県がんセンター	上野 秀樹 国立がん研究センター中央病院	4003	Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial.	Shukai Qin
			4005	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—Efficacy analysis in Japanese and Western patients.	Shuichi Hironaka
			4006	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)	Jordi Bruix
15:00-15:10	Discussion: Q&A				
15:10-15:40	Patient and Survivor Care 内野 慶太 九州医療センター	照井 康仁 がん研有明病院	LBA9500	Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.	Gabriel N. Hortobagyi
			LBA9513	Benefits of immediate versus delayed palliative care to informal family caregivers of persons with advanced cancer: Outcomes from the ENABLE III randomized clinical trial.	J Nicholas Dionne-Odom
			LBA9514	Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness.	Amy Pickar Abernethy
15:40-15:50	Discussion: Q&A				
15:50-16:05	Coffee Break 15分				
16:05-16:35	乳がん - ER/HER2 高野 利実 虎の門病院	佐治 重衡 京都大学	LBA1	Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.	Olivia Paganì
			LBA4	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).	Martine J. Piccart-Gebhart
			500	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.	Kathy Miller
16:35-16:45	Discussion: Q&A				
16:45-17:15	乳がん - Triple Negative 田村 研治 国立がん研究センター中央病院	佐治 重衡 京都大学	1005	Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.	Gunter Von Minckwitz
			1017	Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.	Kenji Tamura
			1019	Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146.	Sujaata Dwadasi
17:15-17:25	Discussion: Q&A				
17:25-17:40	Break 15分				
17:40-18:25	[イブニングセミナー] 辻 晃仁 神戸市立医療センター中央病院	島田 安博 国立がん研究センター中央病院	大腸がん化学療法の新潮流 大鵬薬品工業株式会社		

7月6日 (日曜日)

Time	講師	司会	ASCO演題		
7:30	開場		ID	Abstract Title	Author
8:00-8:45	[モーニングセミナー] 岡本 勇 九州大学	武田 晃司 大阪市立総合医療センター	非小細胞肺癌における分子標的薬の新展開 ファイザー株式会社		
8:45-9:00	Break				
9:00-9:30	婦人科がん 温泉川 真由 国立がん研究センター中央病院	土井 俊彦 国立がん研究センター東病院	LBA5500	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.	Joyce Liu
			5507	Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study.	Aikou Okamoto
			5508	Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.	TAKASHI ONDA
9:30-9:40	Discussion: Q&A				
9:40-10:10	頭頸部がん 清田 尚臣 神戸大学	朴 成和 聖マリアンナ医科大学	6004	Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826).	Maria Grazia Ghossein
			6005	Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).	Kevin J. Harrington
			LBA6008	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).	Martin Schlumberger
10:10-10:20	Discussion: Q&A				
10:20-10:40	泌尿器がん - Prostate Cancer 田畑 健一 北里大学病院	南 博信 神戸大学	LBA2	Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.	Christopher Sweeney
			5008	Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)	Ronald De Wit
10:40-10:50	Discussion: Q&A				
10:50-11:20	泌尿器がん - Nonprostate Cancer 三浦 裕司 虎の門病院	南 博信 神戸大学	4500	Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.	Cora N. Sternberg
			5009	Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.	Robert J. Motzer
			5012	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.	Toni K. Choueiri
11:20-11:30	Discussion: Q&A				
11:30-11:50	Melanoma/Skin Cancers 近藤 俊輔 国立がん研究センター中央病院	清水 俊雄 近畿大学	LBA9008	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.	Alexander M. Eggermont
			S9011	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma	Georgina V. Long
11:50-12:00	Discussion: Q&A				
12:00-12:15	Break				
12:15-13:15	[ランチョンセミナー] 山口 研成 埼玉県立がんセンター	佐藤 温 弘前大学	大腸癌化学療法の最新の知見 中外製薬株式会社		
13:15-13:30	Break				
13:30-14:10	肺がん - Non-smal Cell Metastatic 宿谷 威仁 順天堂大学	岡本 勇 九州大学	8002	First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)	Tony Mok
			8005	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.	Terufumi Kato
			LBA8006	REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy	Maurice Perol
			8008	A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).	Nick Thatcher
14:10-14:25	Discussion: Q&A				
14:25-14:45	肺がん - Small Cell 瀬戸 貴司 国立病院機構九州がんセンター	笠原 寿郎 金沢大学	7503	Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.	Takashi Seto
			*7504	A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605	Koichi Goto
14:45-14:55	Discussion: Q&A				
14:55-15:05	Closing Remarks 山本 信之 和歌山県立医科大学				